- Oxemia TM (Desidustat) is a breakthrough treatment for Anemia associated with Chronic Kidney Disease (CKD) in Patients either on Dialysis or Not on Dialysis
- Oxemia TM (Desidustat) is an oral tablet formulation which is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
- Oxemia TM is the 2nd NCE to be exclusively developed in India from lab to market after Saroglitazar Mg, also a Zydus innovation
- Discovered at Zydus Research Centre, Oxemia TM (Desidustat) is a differentiated best-in-class HIF-PH Inhibitor
Zydus to launch Oxemia (Desidustat) a treatment for Anemia in patients with Chronic Kidney Disease (CKD)
Related Posts
Leave a Reply
Recent News
